Balyasny Asset Management L.P. Makes New $870,000 Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Balyasny Asset Management L.P. purchased a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 187,030 shares of the company's stock, valued at approximately $870,000.

Several other institutional investors have also added to or reduced their stakes in the business. National Bank of Canada FI lifted its holdings in shares of GoodRx by 34.9% during the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after purchasing an additional 2,151 shares during the period. RPO LLC acquired a new position in GoodRx in the fourth quarter valued at approximately $52,000. Versor Investments LP acquired a new position in GoodRx in the fourth quarter valued at approximately $54,000. Verus Capital Partners LLC acquired a new position in GoodRx in the fourth quarter valued at approximately $55,000. Finally, Steward Partners Investment Advisory LLC acquired a new position in GoodRx in the fourth quarter valued at approximately $56,000. Institutional investors and hedge funds own 63.77% of the company's stock.

GoodRx Trading Down 0.6%

Shares of GoodRx stock traded down $0.03 during trading hours on Tuesday, hitting $3.93. The company's stock had a trading volume of 72,839 shares, compared to its average volume of 1,383,370. GoodRx Holdings, Inc. has a twelve month low of $3.68 and a twelve month high of $9.26. The firm has a fifty day moving average of $4.43 and a 200-day moving average of $4.63. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -130.83, a P/E/G ratio of 2.46 and a beta of 1.24. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The business had revenue of $202.97 million for the quarter, compared to analyst estimates of $202.25 million. During the same quarter in the prior year, the company posted $0.08 EPS. The company's quarterly revenue was up 2.6% on a year-over-year basis. Research analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GDRX. The Goldman Sachs Group decreased their price target on GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, May 9th. UBS Group cut their price objective on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Wells Fargo & Company cut their price objective on GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Finally, Truist Financial dropped their price target on GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research report on Thursday, April 10th. Five equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, GoodRx has an average rating of "Moderate Buy" and a consensus target price of $6.55.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.